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The high sensitivity of peptides and proteins to physicochemical stresses during processing
and storage is the major hurdle against its pharmaceutical applications. Peptide-based drug
formulations are commonly prepared as solid dosage forms because more stability can be achieved
in the solid rather than in the liquid state (Ameri and Maa, 2006). The most common methods
to increase the stability of peptides and proteins are drying and the use of stabilizing excipients
(Maltesen and van de Weert, 2008). So far, spray drying and freeze drying are the most popular
methods of drying peptides and protein solutions in the Pharmaceutical industry. Other drying
methods, like spray coating, spray freeze drying (SFD), and supercritical fluid technology and their
different modifications, are mostly used on a small scale, especially for research purposes (Franks
et al., 1991; Marreto et al., 2006). The optimum choice of drying technique will depend mainly on
the economics of drying and on the intended route of drug administration (Webb et al., 2002).
Compared to freeze drying, spray drying is a faster and more economical, single step, drying
method which can be designed as a continuous drying process (Masters, 1972). Spray drying
is suitable for heat-sensitive materials, despite the high temperatures of the drying gas, owing
to the cooling effect of the evaporating solvent which keeps the droplet temperature relatively
low (Masters, 1972). Another advantage of spray drying technique is its ability to control the
particle size and the morphology of the dried powder by varying the process parameters and
the formulation factors (Masters, 1972). Moreover, spray dried powders are commonly prepared
when the intended route of administration is via inhalation, so that this technique is of prime
importance for pulmonary delivery of protein pharmaceuticals (Maaand and Prestrelski, 2000; Lee,
2002). However, low powder yield is still the major drawback in the development of spray dried
pharmaceuticals because of small amounts of expensive active ingredients which are available after
the early stages of development (Broadhead et al., 1994). Other instability problems encountered
when spray drying an aqueous solution of a pure protein, include aggregation and subsequent
loss of activity (Adler and Lee, 1999; Tzannis and Prestrelski, 1999). These instabilities can be
ameliorated by formulation measures, such as the inclusion of disaccharides or surfactants in the
liquid feed to prevent protein aggregation or inactivation, a strategy that can be also implemented to
improve storage stability of therapeutic peptides, proteins and heat-sensitive enzymes without great
denaturation (Broadhead et al., 1992, 1993; Adler and Lee, 1999). The mechanisms of preferential
exclusion, water replacement and glass immobilization are quite similar to those involved in
lyophilization to explain the sugar’s role in stabilizing protein and peptide molecules during the
drying process (Lee, 2002).
During spray drying, the way in which stabilizing excipients react with proteins can control the
choice of the additives and the processing conditions to preserve the protein properties, stability,
and biological activity. Surfactants such as Cremophor R©EL and Pluronic R©F-127, and sugars like
cyclodextrin and inulin, maintained lysozyme thermal stability after spray drying. Pluronic R©F-
127 prevented lysozyme aggregation meanwhile preserved its biological activity similar to
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β-cyclodextrin and inulin which maintained lysozyme biological
activity. The improved stability of the spray dried lysozyme using
Pluronic R©F-127 as a stabilizer revealed the promising delivery of
proteins via inhalation and injections (Haj-Ahmad et al., 2013).
It is impartial to conclude that the most common stresses
involved during spray drying of different peptides and protein
molecules are adsorption, shear stress, thermal stress, and
dehydration stress. These stresses can result in unfolding of
protein structure with subsequent aggregation and denaturation,
thus creating substantial worries about possible loss of their
biological activity (Lee, 2002). In addition to the influence
of formulation parameters, the extent of protein degradation
during spray drying is greatly affected by the spray drying
process conditions such as inlet temperature and spray rate,
which also have an impact on the particle morphology and
the aerodynamic properties of the powder (Cabral-Marques
and Almeida, 2009). Therefore, judicious selection of machine
size and process parameters allows the preparation of protein
loaded inhalable powders characterized by minimal protein
damage, suitable residual moisture content, good aerodynamic
properties, and satisfactory storage stability (Lee, 2002; Chan,
2003).
Recent developments achieved in the area of particle
engineering via spray drying in the last two decades were
coinciding with the development of different pulmonary
therapeutics administered traditionally by injection (Patton and
Byron, 2007). The pulmonary route was found to be beneficial
for systemic delivery of different proteins and peptides (Johnson,
1997), in particular insulin (Patton et al., 1999). Micro- and
nanoparticles fabrication via spray drying has been introduced
as an attractive manufacturing technique in the pharmaceutical
FIGURE 1 | Schematic design of the Nano Spray Dryer B-90 and its products of nano/microparticles with an average size range of 300nm–5µm.
engineering owing to its wide applicability in addition to its
contribution to high stability and efficacy of the final particulate
dosage form (Vehring, 2008).
The spray drying technology received a great attention for
the formulation of micro/nanoparticulate controlled delivery
systems (Giunchedi and Conte, 1995; Gavini et al., 2003). It
can be used as a rapid and convenient process to prepare
microparticles with precise physical morphologies (Alcock et al.,
2002). Spray drying has been employed to enhance drug solubility
and bioavailability of active ingredients, modified release, and
pulmonary delivery of proteins or vaccines (Cal and Sollohub,
2010; Sollohub and Cal, 2010). Recent studies highlighted
the potential use of spray drying as an effective technology
to deliver macromolecular therapeutics encapsulated in poly
(d,l-lactide-co-glycolide) (PLGA) polymer and its derivatives.
PLGA has been studied most intensively to encapsulate different
types of proteins through spray drying processing. However,
the implementation of double emulsification (w/o/w) or phase
separation techniques is a prerequisite before the application of
the spray drying technique (Bittner et al., 1998; Blanco-Príeto
et al., 2000; Giunchedi et al., 2001).
Current progress in the spray drying paved the road to
introduce a new advanced technology such as the Nano Spray
Dryer B-90, recently developed by BÜCHI Labortechnik AG,
which resulted in high particle recovery rates up to milligram
sample amounts of powder particles with particle sizes between
300 nm and 5µm (Figure 1). The Nano Spray Dryer was
designed to generate millions of precisely sized tiny droplets
every second by using a piezoelectric driven, vibratingmembrane
in the spray head. The final, dried particles are separated by
the aid of an electrostatic particle collector with high product
Frontiers in Pharmacology | www.frontiersin.org 2 July 2015 | Volume 6 | Article 140
Haggag and Faheem Nano spray drying for peptides and proteins
recovery (Li et al., 2010; Bürkia et al., 2011; Heng et al., 2011; Lee
et al., 2011; Schmid et al., 2011; Schafrothb et al., 2012).
The main drawbacks of classical spray drying were the
high sample volume required (minimum 50mL), the low yield
obtained (maximum 70%), and the big particle size (minimum
2µM). However, by using the Nano Spray Dryer with its new
advanced technology of the spray head, the heating system, and
the electrostatic particle collector, the sample amount or volume
can be as small as 200mg or 2mL, the final product yields
increased up to 90%, the particle sizes decreased up to 300 nm
with narrow size distribution, and, eventually, fast drying process
(up to 150ml/h) was attained (Li et al., 2010; Bürkia et al., 2011;
Heng et al., 2011; Lee et al., 2011; Schmid et al., 2011; Schafrothb
et al., 2012).
The major advantage of having nanosize powder, especially
in the field of proteomics and genomics, is to enhance the
stability and therapeutic potential of these drugs to become
more effective and less toxic. The in vivo biodistribution and
clearance of these drugs mainly depend on their size (Wang
et al., 2011). Nanosize is a key parameter that significantly affects
cellular and tissue uptake of nanoparticles, as it influences their
internalization mechanisms. Submicron size particles are taken
up more efficiently compared to the larger size microparticles
(Zauner et al., 2001).
This technology is widely used in different pharmaceutical
application owing to its unique features of processing the small
sample amounts and the high yields produced. It is ideal
for the spray drying of precious samples, inhalable drugs as
protein dry powder inhalers and stabilization of heat-sensitive
vaccines, proteins, and hormones. On the other hand, it can be
used for fabrication of liposomes and polymeric nanoparticles
(nanocapsules of biodegradable and biocompatible polymers)
encapsulating different drugs for controlled drug release and
higher bioavailability. Moreover, this technique can be used for
drying of various excipients for controlled drug release purposes
as hydroxypropyl methylcellulose (HPMC), trehalose, mannitol,
and lactose (Li et al., 2010; Bürkia et al., 2011; Heng et al.,
2011; Lee et al., 2011; Schmid et al., 2011; Schafrothb et al.,
2012).
This novel spray drying approach can be effectively used
as an alternative technique for nanoparticle engineering (Li
et al., 2010). The Nano Spray Dryer B-90 can be used for a
wide variety of applications including spray drying of solutions,
nanosuspensions, nanoemulsions, or micro and nanoparticles
as well as for structural transformations. Also, it has been
employed for the preparation of submicron polymeric particles,
the encapsulation of nanoemulsions (Schmid et al., 2011), and
the drying of pharmaceutical excipients and models of active
ingredients (Heng et al., 2011). Recently, Nano Spray Dryer B-90
has been applied for producing protein nanoparticles (Lee et al.,
2011).
Moreover, the optimization of the formulation parameters,
like the polymer molecular weight, degradation characteristics
and the drug–polymer interactions besides spraying parameters
such as spray mesh diameter, spray rate, sample concentration,
and sample flow rate had a great impact on the particle size,
production yield, encapsulation efficiency, solid state solubility,
and controlled release profiles of the engineered nanoparticles (Li
et al., 2010).
Previous studies showed that different proteins like bovine
serum albumin (BSA) and β-galactosidase could be spray
dried without activity loss using the Nano Spray Dryer B-90.
Optimization of the process setting like the inlet temperature, the
spraymesh size and the ethanol content resulted in respirable size
and high yields (approximately 90%) in case of β-galactosidase.
The impact of other experimental conditions as BSA solution
concentration, stabilizer concentration, drying air flow rate on
the aerodynamic properties of protein nanoparticles offered a
simple and alternative approach for drug delivery of protein
nanoparticles (Bürkia et al., 2011; Lee et al., 2011).
Nano Spray Dryer was used in cost effective production
of high yields of vildagliptin nanospheres designed to treat
type 2 diabetic patients. These mucoadhesive nanospheres were
marked by their narrow particle size distribution of 445 nm.
This favorable nano size distribution made it suitable for oral
administration (Harsha et al., 2015).
The spray drying of peptides and proteins from aqueous
and/or organic liquid feeds can be effectively achieved by using
the Nano Spray Dryer. Small therapeutic peptides and proteins,
which showed high water solubility, can be efficiently dried from
their aqueous liquid feeds in an economical way. Other peptides,
which show poor aqueous solubility, are difficult to be dried
from their aqueous feeds; therefore spray drying of these peptides
dissolved in non-aqueous solvents may be necessary to meet the
demands on economical production and good particle formation.
Characterization of the spray dried protein regarding the particle
morphology, the physical state, the residual content of water and
other organic solvent, the glass transition temperature, and the
biological activity should be used as criteria for judging successful
protein powder formulation.
In addition to the solubility behavior of different peptides
and proteins, the behavior of different excipients for protein
stabilization and possible stress factors experienced by a protein
during spray drying can be controlled to improve the final
product. A variety of therapeutic peptides and heat sensitive
model enzymes could be successfully spray dried without activity
loss using the Nano Spray Dryer when the optimized process
settings were adjusted to produce dried protein particles of
respirable size in a high yield. Other essential optimization is to
identify stabilizers, which are better suited to protect different
proteins during the spray drying process with respect to the
powder’s inhalation properties, the storage stability and the shelf
life of the final product.
The major drawbacks are represented when the harsh
processing steps render proteins or peptides more susceptible
to physical and chemical instability through aggregation,
denaturation, oxidation, and cleavage. Proteins are exposed
to several shear stresses like shaking, pumping, and nozzle
atomization during this spray drying process. Adsorption of
proteins and peptides to different interfaces can result in
unfolding of their structure that finally leads to the formation of
aggregates. However, thermal stress is very important as proteins
lose their native structure when exposed to sufficiently elevated
temperatures and the native state of a protein is stable in a
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limited temperature range. Removal of water by dehydration
processes, like spray drying, might lead to structural modification
and protein denaturation.
However, the pros and cons of Nano Spray Dryer on the level
of nanoparticles formulation are quite different. The recovery of
small particles intended for inhalation is significantly low using
the classic spray dryer because of their poor separation in cyclone
collectors owing to their low mass, a major drawback which
was successfully overcome by recent developments and progress
of nano spray drying technology as discussed earlier. At the
nanoparticles’ formulation level, the technology was successfully
utilized for controlled delivery of peptides and proteins. The
technique involves rapid transformation of micro and nano-
dispersed droplets into dried particles by atomization of a liquid
feed. Nevertheless, a high solid content in the liquid feed is a
prerequisite to achieve good particle formation and to minimize
the production costs.
Nano Spray Dryer is a very fast, easy and cost-effective powder
generating device, which can be used to prepare powders in dry
forms with high yields. Owing to its simplicity as a one step
process, the emulsification/spray drying method has been used as
an alternative to double emulsificationmethod for the fabrication
of PLGAmicro and nanospheres containing water-soluble drugs.
Moreover, this spray drying method has an additional advantage
in the preparation of sterile injectable particulate delivery systems
because it can be conducted in an aseptic condition, as the device
could be easily cleaned and sterilized and the atomized air could
be filtered. On the other hand, the incorporation of stabilizers
such as poly (vinyl alcohol) and other amphiphilic surfactants,
which are difficult to remove, is not recommended to minimize
the preparation efforts and to prevent the side-effects from the
residual surface located surfactant.
The hydrophobic ion pairing (HIP) technique based upon
spray drying can be employed as a simple process to improve
hydrophilic peptide encapsulation in lipophilic carriers to form
micro and nanoparticles. These micro and nanoparticles can
modify the release of the encapsulated peptides while retaining
the biological activity (Alcock et al., 2002).
Combination of (HIP) method with organic spray drying
and emulsion solvent diffusion method enhanced insulin
encapsulation and release from PLGA nanoparticles. These
nanoparticles enhanced the oral bioavailability of insulin
thereby it was promising for oral insulin delivery (Sun et al.,
2015).
While PLGA nanoparticles encapsulating different drugs as
peptides, proteins and small molecules can be produced with
controlled physicochemical properties using Nano Spray Dryer,
the ability to process small volumes to produce a high yield
of small particles still represents the major advantage of this
relatively new approach.
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